Medical Oncology · Mersin
At every moment of life, for you.
Assoc. Prof. Dr. Ali Oğul · Medical Oncologist, Mersin
WhatsApp and telephone: +90 530 250 54 85
About
Who is Assoc. Prof. Dr. Ali Oğul?
Assoc. Prof. Dr. Ali Oğul is a medical oncology specialist working in the Division of Medical Oncology at Mersin University Faculty of Medicine Oncology Hospital. He graduated from Ankara University Faculty of Medicine and completed his internal medicine and medical oncology specialty training at Çukurova University Faculty of Medicine. After working at the University of Health Sciences Adana City Training and Research Hospital, he has been at Mersin University since December 2024; he was awarded the title of associate professor in 2021.
He works on the evaluation, treatment planning and follow-up of patients diagnosed with cancer. He plans systemic treatments, including chemotherapy, immunotherapy, targeted therapies and hormone therapies, with a multidisciplinary approach. He considers the results of genetic analyses performed on tumour tissue or blood, such as next-generation sequencing (NGS), together with the patient's general condition and preferences, and adopts an individualised treatment approach.
He continues his academic work mainly on lung, breast and digestive system cancers and has served as an investigator in international multicentre clinical trials. The full list of his publications and academic activities is on the Academic page. He has been a member of the Turkish Society of Medical Oncology since 2015.
- Specialty
- Medical Oncology (Internal Medicine)
- Academic title
- Associate professor (2021)
- Institution
- Mersin University Faculty of Medicine Oncology Hospital, Division of Medical Oncology
- ORCID
- 0000-0003-4886-7060
- Education
- Ankara University Faculty of Medicine; Çukurova University Faculty of Medicine (internal medicine and medical oncology specialty)
NewLast updated: 28 October 2026
Latest Developments: new approvals and reimbursements
FDA approvals, licences in Turkey, changes in SGK reimbursement and promising studies in peer-reviewed journals; each is compiled with its source and reviewed by Assoc. Prof. Dr. Ali Oğul.
New drug approvals and indication expansions
- Talazoparib with enzalutamide receives FDA approval in hormone-sensitive metastatic prostate cancer with HRR gene mutations
- Dostarlimab received FDA accelerated approval for stage II–III MSI-H/dMMR locally advanced rectal cancer
- In BCG-unresponsive non-muscle invasive bladder cancer, the approval of nogapendekin alfa inbakicept was expanded to include patients with papillary-only tumors
- Atezolizumab, together with adjuvant chemotherapy, received FDA approval for stage III dMMR colon cancer
- Tucatinib received FDA approval as maintenance therapy in HER2-positive metastatic breast cancer
Products newly licensed in Turkey
- Mirvetuximab soravtansine received marketing authorisation in Turkey for folate receptor alpha-positive, platinum-resistant ovarian cancer
- Two targeted drugs received marketing authorisation in Turkey for breast cancer with PIK3CA/AKT pathway alterations
- Selpercatinib, used in RET fusion-positive lung cancer, received marketing authorisation in Turkey
SUT and reimbursement changes in the Official Gazette
- SGK updated the reimbursement conditions for trastuzumab emtansine and pertuzumab in HER2-positive breast cancer
- SGK expanded the reimbursement scope for abiraterone and darolutamide in prostate cancer
- SGK removed the age limit of 65 for the combination of nivolumab and ipilimumab in advanced kidney cancer
- SGK reorganised the reimbursement conditions for immunotherapy in lung cancer
Studies published in peer-reviewed journals that do not yet imply approval
- In HER2-positive breast cancer, adding tucatinib after radiosurgery for brain metastases supported intracranial disease control (BRIDGET, phase 2)
- In EGFR-mutant, MET-overexpressing advanced lung cancer, first-line savolitinib plus osimertinib prolonged disease control (SANOVO)
- Sacituzumab tirumotecan prolonged survival compared with chemotherapy in previously treated advanced endometrial cancer (TroFuse-005)
- In relapsed osteosarcoma, the antibody–drug conjugate risvutatug rezetecan prolonged disease control compared with chemotherapy (ARTEMIS-011)
- In dMMR advanced endometrial cancer, chemotherapy-free first-line pembrolizumab prolonged disease control compared with chemotherapy (KEYNOTE-C93)
48 records, 14 cancer types. These pages are for information only; the approval of a drug or the publication of a study does not mean it is suitable for every patient. Please discuss personal treatment decisions with your physician.
See all developmentsMy approach: Multidisciplinary Oncology
Cancer treatment is the work of a team, not of a single physician.
Each patient's file is reviewed together in tumour boards attended by specialists in medical oncology, surgical oncology, radiation oncology, pathology, radiology, nuclear medicine and, when needed, geriatrics and haematology. The treatment plan is built by considering the stage of the disease, the biological characteristics of the tumour, the patient's general health and personal preferences together.
My aim is to determine the most suitable evidence-based plan together with my patient, through transparent communication.
Assoc. Prof. Dr. Ali Oğul
Medical Oncology
Individualised, evidence-based evaluation for cancer diagnosis, treatment planning and follow-up.
Medical oncology is a branch of medicine concerned with the diagnosis, treatment and follow-up of cancer. Different treatment approaches are considered depending on the cancer type and the characteristics of the disease.
Treatments
Current Approaches to Treatment
Genetic and Molecular Profile
Genetic tests performed on tumour tissue or blood (liquid biopsy) look for alterations that can guide treatment. Markers such as EGFR, ALK, KRAS, BRCA, HER2 and MSI can be decisive in choosing treatment.
Targeted Drugs (Targeted Therapy)
These are drugs that target a specific genetic alteration or protein in the tumour cell. In suitable patients they can offer an effective treatment option while causing less harm to healthy cells.
Immunotherapy
These are treatments that enable the immune system to recognise and fight cancer cells. They are used in many tumours, including lung, melanoma, kidney, bladder and some digestive system cancers.
Antibody-Drug Conjugates
These are newer-generation treatments that carry a chemotherapy drug directly to the tumour cell by means of an antibody. They have widened treatment options in breast and some other cancers.
Hormone Therapy
In hormone-sensitive tumours such as breast and prostate cancer, it aims to reduce the effect of the hormones that support tumour growth. It can be given alone or together with other treatments.
Chemotherapy and Combination Treatments
It is given with protocols in line with current guidelines and, when needed, together with targeted drugs or immunotherapy. The dose and duration are adjusted individually according to the patient's condition.
Supportive Care and Quality of Life
Managing nausea, pain, fatigue and nutrition problems is an integral part of treatment. The aim is to preserve quality of life throughout treatment.
The information in this section is for general information only; which treatment is appropriate is determined by an individual evaluation by a physician.
More information about treatmentsMultidisciplinary Approach
Comprehensive evaluation in collaboration with colleagues
When needed, we evaluate our patients together with our valued colleagues in the relevant fields.
Geriatric Oncology
In older patients, the treatment decision is based on biological age and functional status rather than calendar age. Patients who score 14 or below on the eight-question G8 screening test undergo a comprehensive geriatric assessment. Sarcopenia, the loss of muscle mass and strength, is taken into account in treatment planning because it can increase the side effects of chemotherapy. We carry out these assessments together with Assoc. Prof. Dr. Çağatay Çavuşoğlu in the field of geriatrics.
CollaborationAssoc. Prof. Dr. Çağatay ÇavuşoğluGeriatrics
Haematological toxicity
Haematological side effects that can appear in blood counts during chemotherapy (haematological toxicity) are monitored closely. The assessment and management of these conditions are planned together with haematology.
CollaborationAssoc. Prof. Dr. Mahmut Bakır KoyuncuHaematology
We thank our valued colleagues for their contributions to our patients.
Academic
Scientific work
Alongside his clinical work, he has articles published in national and international journals, conference papers, book chapters and roles in multicentre clinical trials.
- 46Articles
- 26Conference papers
- 9Clinical trials and projects
- 5Book chapters
Compiled from Mersin University APBS records (updated: 01.09.2026).
ORCID · verifiable academic identity0000-0003-4886-7060Mersin and the surrounding region
Medical oncology in Mersin and the surrounding region
Assoc. Prof. Dr. Ali Oğul sees patients in the medical oncology outpatient clinic at Mersin University Faculty of Medicine Oncology Hospital (Çiftlikköy Campus, Yenişehir). Planning of systemic treatments such as chemotherapy, immunotherapy, targeted (smart-drug) therapies and hormone therapies, monitoring of side effects and post-treatment follow-up are carried out here.
Outpatient clinic
Outpatient clinic hours
Monday–Friday, 08:00–16:00
Outpatient clinic days may change depending on administrative duties. Please confirm the day and time via WhatsApp before you come.
Region
From which areas?
You can apply from all districts of Mersin (Yenişehir, Mezitli, Toroslar, Akdeniz, Tarsus, Erdemli, Silifke, Anamur, Bozyazı, Mut, Gülnar) and from neighbouring provinces such as Adana, Osmaniye, Hatay, Karaman and Antalya. Assoc. Prof. Dr. Oğul, who was born in Anamur, has also worked in Bozyazı.
Second opinion
Requesting a second opinion
You can send your request and reports online via WhatsApp; the evaluation takes place face to face in the outpatient clinic. Process and required documents
Getting there
Getting to the hospital
Bus and minibus stops are in front of the hospital. Bus: 111, 121, 177, 11M, 12M, 19M, 23M, 28M, 29M, 36M, 37M, 48M, 69M, 74M, 76M. Minibus (dolmuş): Mezitli Koop-1, Pozcu Koop-7. Source: hastane.mersin.edu.tr; route information may change.
Frequently asked: appointments and travel
How do I make an appointment for a medical oncology consultation in Mersin?
You can write via WhatsApp (+90 530 250 54 85) or call the same number. The outpatient clinic runs on weekdays from 08:00 to 16:00; because the days can change with administrative duties, we recommend confirming via WhatsApp.
What should I do before coming from Tarsus, Erdemli, Silifke or Anamur?
Before setting out, contact us via WhatsApp to confirm the clinic day and send your reports. This makes clear which documents you should bring to the consultation. The evaluation takes place in the outpatient clinic of Mersin University Oncology Hospital.
Can I apply for a second opinion from Adana, Hatay, Osmaniye or Karaman?
Yes. The request and the documents can be sent online via WhatsApp; the second-opinion evaluation takes place face to face in the outpatient clinic in Mersin.
What is the difference between a medical oncologist and a radiation oncologist?
A medical oncologist plans and monitors drug treatments such as chemotherapy, immunotherapy, targeted drugs and hormone therapy. A radiation oncologist plans and delivers radiotherapy. In most patients the two specialties decide together in the tumour board.
What should I bring to the consultation?
Pathology report, imaging reports and their CDs, discharge summary, blood tests and the list of medicines you take (by active ingredient name).
Contact
Get in touch for appointments and information
To make an appointment, you can send a WhatsApp message or call +90 530 250 54 85.
Just send your name and a short note via WhatsApp; we will get back to you to arrange a suitable day and time.
You can send your request for a second opinion and your current pathology, imaging and discharge reports via WhatsApp; the evaluation takes place face to face in the outpatient clinic. Process and required documents
The content of this website is for general information only and does not replace an individual medical assessment, diagnosis or treatment recommendation.